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Abstract
Background: Reliability of cardiac troponin-I assays under real-time conditions has not been
previously well studied. Most large published cTnI trials have utilized protocols which required the
freezing of serum (or plasma) for delayed batch cTnI analysis. We sought to correlate the presence
of the acute ischemic coronary syndrome (AICS) to troponin-I values obtained in real-time by three
random-mode analyzer immunoassay systems: the Beckman ACCESS (BA), the Bayer ACS:180
(CC) and the Abbott AxSYM (AX).
Methods: This was an observational prospective study at a university tertiary referral center.
Serum from a convenience sampling of telemetry patients was analyzed in real-time for troponin-I
by either the BA-CC (Arm-1) or BA-AX (Arm-2) assay pairs. Presence of the AICS was determined
retrospectively and then correlated with troponin-I results.
Results: 100 patients were enrolled in Arm-1 (38 with AICS) and 94 in Arm-2 (48 with AICS). The
BA system produced 51% false positives in Arm-1, 44% in Arm-2, with negative predictive values
of 92% and 100% respectively. In Arm-1, the BA and the CC assays had sensitivities of 97% and 63%
and specificities of 18% and 87%. In Arm-2, the BA and the AX assays had sensitivities of 100% and
83% and specificities of 11% and 78%.
Conclusions: In real-time analysis, the performance of the AxSYM and ACS:180 assay systems
produced more accurate troponin-I results than the ACCESS system.
Background
Physicians are frequently called upon to care for patients
presenting with symptoms suggestive of the acute
ischemic coronary syndrome (AICS). Over the past few
years a number of cardiac markers, including myoglobin,
cardiac troponins and creatine kinase isoenzyme-MB,
have become available to assist with the management and
triage of patients suspected of having myocardial injury
[1,2]. Cardiac Troponin-I (cTnI) has been shown to be a
very sensitive and specific marker in this respect [1-5]. To
date, the large published cTnI trials have utilized proto-
cols which required the freezing of serum (or plasma) for
delayed batch cTnI analysis. The process of freezing and
thawing incorporates extra centrifugation and settling
steps that are not performed when the assay is run under
real-time conditions which may alter their performance
characteristics [6-10]. Additionally, each cTnI assay sys-
tem currently available utilizes a unique antibody to a
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specific cTnI epitope, some of which are inherently less
specific than others [7,11,12].
At our institution, we appeared to have an inappropriately
high rate of false positive cTnI values when our assays
were performed under real-time conditions, despite strict
adherence to the manufacturer's methodology. This phe-
nomenon was apparently not unique to our medical
center (verbal communications). From whatever cause,
obtaining false positive cTnI values can have a substantial
impact on a patient's cardiac evaluation.
There are currently more than half a dozen cTnI quantita-
tive analysis systems available in the U.S. with new gener-
ation assays being developed [13]. Despite the literature
purporting excellent clinical utility of the cTnI marker, the
reliability of these assays, when used under real-time clin-
ical conditions, has not been well studied. Additionally,
assays are often inadequately appraised prior to their
introduction into clinical use [14]. Cardiac TnI results
published from large clinical trials to date have been
obtained from assays performed using thawed specimens.
This trial was done to assess the level of agreement and
clinical accuracy between cTnI values determined in real-
time, using fresh serum, in patients undergoing AICS eval-
uation, by three widely used random-mode (as opposed
to batch) analyzer immunoassay systems: the Beckman
ACCESS (BA) paramagnetic-particle, chemiluminescent
immunoassay versus both the Bayer ACS:180 (CC) chemi-
luminescent immunoassay and the Abbott AxSYM (AX)




The investigation was performed in accordance with the
Declaration of Helsinki with the hospital's institutional
review board granting approval of this research project.
This was an observational study performed at a university
tertiary referral center with prospective blood specimen
collection and patient assessments and retrospective
determination of the AICS. A convenience sample of adult
cardiac telemetry unit patients being treated and/or
observed for possible cardiac ischemia, were selected to
participate. The diversity of the patient population
enrolled at our institution is diverse and not unique when
compared with other major medical centers [15]. All
patients with hematological samples ordered by the pri-
mary care physician for CKMB analysis as part of the
patient's myocardial assessment, were eligible. All cTnI
specimens were drawn between eight and 24 hours after
the onset of symptoms.
Blood samples were obtained in accordance with the
standard procedures of the hospital. Blood was drawn
into evacuated gel tubes for serum preparation, kept at
room temperature to allow clotting, and transported
directly to the pathology laboratory for biochemical anal-
ysis. In the first phase of the study (Arm-1), samples were
processed on the BA and CC analyzers. For the second
phase (Arm-2), samples were processed on the BA and AX
analyzers. Limited resources restricted comparing all three
machines simultaneously. At the time of the study, the
hospital was routinely using the BA analyzer. The treating
physician was blinded to all other cTnI results obtained as
part of the study with the patient's treatment care plans
continuing unchanged.
Laboratory analysis
All samples were run simultaneously on the BA analyzer
(Access Immunoassay System, Beckman Instruments, Inc.
(formerly Sanofi-Synthelabo, Inc.)) and either the CC
analyzer (Bayer-Centaur ACS:180 Automated Chemiluni-
nescence System, Bayer Industries (formerly Chiron Diag-
nostics Corp.)) in Arm-1, or the AX analyzer (AxSYM
System, Abbott Laboratories) in Arm-2. Samples were
strictly processed according to the manufacturer's specifi-
cations with regards to centrifugation, filtering, tempera-
ture control and other specimen, reagent and equipment
handling procedures [16-18]. Specimens were then split
and run on each analyzer pair simultaneously. The analyz-
ers were operated at the manufacturers' specifications with
performance reliability maintained within the limits spec-
ified by the manufacturer, and were dedicated to running
only the cTnI assays. All three first generation systems uti-
lized random-mode (as opposed to batch) sample analy-
sis to obtain real-time results. The manufacturers'
predetermined calibrations established limits for negative
(lowest limit of detection), indeterminate and positive
(based on ROC analysis for the diagnosis of ST elevation
MI) values for each assay system. Cutoff values were:
<0.03, 0.03–0.15, >0.15 ng/ml for the BA, <0.15, 0.15–
1.4, >1.4 ng/ml for the CC, and <0.4, 0.4–1.9, >1.9 ng/ml
for the AX assays. All samples were run in duplicate with
mean cTnI values used for data analysis. Quality control
samples were run at normal and high levels. For this
study, all indeterminate values were considered positive
in order to incorporate the spectrum of unstable angina
(and micro-infarct) into the data analysis [5,19,20].
Definitions
The acute ischemic coronary syndrome (AICS) is defined
as a continuum of myocardial ischemia ranging from
unstable angina, which may be associated with minor
myocardial damage, to the extensive tissue necrosis of
acute myocardial infarction [21]. The diagnosis of AMI
was determined by using CK-MB enzyme assay results and
the World Health Organization (WHO) criteria [22,23].
Unstable angina was defined as new onset, severe orBMC Emergency Medicine 2004, 4:2 http://www.biomedcentral.com/1471-227X/4/2
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accelerated angina, subacute angina at rest or acute angina
at rest (type IIIB in the Braunwald's classification) [24].
Clinical assessment
The likelihood of the patient having the AICS was deter-
mined retrospectively. The diagnostic categorization of
the AICS as the cardiac endpoint was made if any of the
following criteria were present: acute myocardial infarc-
tion (AMI), non-Q wave MI, or unstable angina. All parts
of the hospital record were reviewed including the ED
chart, laboratory results, 12-lead ECG's, the results of any
cardiac provocative testing or catheterization performed,
and the diagnoses of the clinician responsible for the care
of the patient. The chart review covered a period from two
weeks prior to the index hospitalization to four weeks
after hospital discharge in order to capture any recent
prior infarcts or short-term cardiac event occurring within
the subsequent thirty days. Of note, our institution is the
only tertiary medical center in the region and patients
with serious illness are unlikely to have been seen else-
where. AICS was determined by two independent trained
reviewers for each patient. Both reviewers remained
blinded to all cTnI assay results. Troponin-I was not used
as a criteria for establishing the diagnosis of the AICS or
myocardial infarction to avoid biased outcome. A consen-
sus determination was then established when the review-
ers disagreed. Demographic data (sex, age and race) were
also recorded.
Statistical analysis
All results were entered into an Excel (Microsoft, Red-
mond, WA) spread sheet. Sensitivity, specificity, positive
and negative predictive values, kappa and Bland-Altman
plots were generated using Stata v7.0 (StataCorp. 2001.
Stata Statistical Software, College Station, TX). There was
an enrollment size of 100 samples per group although no
a priori statistical determination of sample size was
performed.
Results
In Arm-1 (BA vs. CC), a total of 100 patients were
enrolled, of which 59% were males, 72% Caucasians,
with an average age of 65 years. In Arm-2 (BA vs. AX), a
total of 94 patients were enrolled, of which 53% were
males, 64% Caucasians, also with an average age of 65
years.
In Arm-1, 38 patients (38%) had a diagnosis consistent
with the AICS, and in Arm-2, there were 48 patients
(51%). The inter-rater agreement (kappa) of AICS was
0.89 for both arms of the study. Table 1 and Table 2 sum-
marize the cTnI values and the AICS status for patients in
each of the two arms in this study. For Arm-1, the percent
of negative cTnI values for BA and CC were 12% (95%CI:
6%, 20%) and 68% (95%CI: 58%, 77%) respectively. For
Arm-2, the percent of negative cTnI values for BA and AX
were 5% (95%CI: 2%, 12%) and 47% (95%CI: 36%,
57%) respectively.
Table 3 summarizes the sensitivity, specificity, negative
and positive predictive values of the three assays using the
cut-off points of: BA (0.03 ng/ml), CC (0.15 ng/ml), and
AX (0.40 ng/ml) to incorporate both the indeterminate
and the positive values into the AICS analysis. There was
no predominant diagnosis seen among those patients
with a false positive cTnI result. Table 4 summarizes the
discordant data for those patients who did not meet the
criteria for the AICS, yet had a positive cTnI result (false
positive value) by both assay pairs. The Bland-Altman
plots (Figures 1 and 2) suggest that by performing a linear
transformation the analyzers would yield similar results
and that the differences in the diagnostic accuracy
between the analyzers may have been in part due to
differences in the cut-off points chosen by the manufac-
turers. However, when we recalculated the statistics using
the transformed data, no significant changes in sensitivi-
ties, specificities, positive or negative predictive values
were found.
Table 1: cTnI Values and the AICS Clinical Decision: Arm-1
BA cTnI Value1 CC cTnI Value2 AICS Present # of Samples AICS Not Present # of 
Samples
Negative Negative 1 11
Negative Indeterminate 0 0
Negative Positive 0 0
Indeterminate Negative 10 39
Indeterminate Indeterminate 9 7
Indeterminate Positive 2 0
Positive Negative 3 4
Positive Indeterminate 3 1
Positive Positive 10 0
1 BA Assay: negative <0.03 ng/ml, indeterminate = 0.03–0.15 ng/ml, positive >0.15 ng/ml 2 CC Assay: negative <0.15 ng/ml, indeterminate = 0.15–
1.40 ng/ml, positive >1.40 ng/BMC Emergency Medicine 2004, 4:2 http://www.biomedcentral.com/1471-227X/4/2
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The sensitivity and specificity of the cTnI assays found in
our study compared to those published by the manufac-
turers are shown in Table 5, with the manufacturers' cut-
offs selected to determine the more specific diagnosis of
acute myocardial infarction (instead of the broader diag-
nosis of the AICS) [16-18].
Discussion
Cardiac Troponin-I is frequently used as a marker for the
evaluation of patients with AICS [1,3,25]. Levels of cTnI
are, on average, detectable four to six hours from the onset
of chest pain, peaking in twelve hours and remaining ele-
vated for three to ten days, making it an ideal marker for
the detection of both acute as well as delayed AICS pres-
entations [26]. Also, cTnI has been shown to be more sen-
sitive than CK-MB mass assays for the detection of
subsequent myocardial events in those patients present-
ing to the ED with chest pain [5,27].
Unlike Cardiac Troponin-T, which is marketed by a single
manufacturer, there are more than half a dozen cTnI
quantitative analysis systems currently available [28].
Surprisingly, the clinical reliability of these assays when
used in real-time has not been well investigated. As our
study shows, the ability of these assays to determine real-
time quantitative cTnI values, are not equal. Both the AX
and the CC assay systems performed much more accu-
rately than did the BA system, which produced a high
number of false positive values. Recently, a second gener-
ation ACCESS assay was marketed, improving on some of
the limitations of its first generation [13]. As with any
assay, its clinical sensitivity and specificity with the fresh
specimen cTnI values obtained needs thorough
clarification.
When compared to the manufacturer's published sensitiv-
ity and specificity data, all three assays yielded lower val-
ues with the exception of the sensitivity for the BA assay.
This may be due to our study protocol in which we chose
Table 2: cTnI Values and the AICS Clinical Decision: Arm-2
BA cTnI Value1 AX cTnI Value2 AICS Present # of Samples AICS Not Present # of 
Samples
Negative Negative 0 4
Negative Indeterminate 0 1
Negative Positive 0 0
Indeterminate Negative 6 22
Indeterminate Indeterminate 0 4
Indeterminate Positive 2 1
Positive Negative 2 10
Positive Indeterminate 0 2
Positive Positive 38 2
1 BA Assay: negative <0.03 ng/ml, indeterminate = 0.03–0.15 ng/ml, positive >0.15 ng/ml 2 AX Assay: negative <0.40 ng/ml, indeterminate = 0.40–
1.90 ng/ml, positive >1.90 ng/ml
Table 3: Correlation Between cTnI Results and the Presence of the AICS
Arm-1 (BA vs. CC)
SENS SPEC PPV NPV
BA-AICS 1 (95% CI) 97 (86, 100) 18 (9, 30) 42 (32, 53) 92 (62, 100)
CC-AICS 2 (95% CI) 63 (46, 78) 87 (76, 94) 75 (57, 89) 79 (68, 88)
Arm-2 (BA vs. AX)
SENS SPEC PPV NPV
BA-AICS (95% CI) 100 (93, 100) 11 (4, 24) 54 (43, 65) 100 (48, 100)
AX-AICS 3 (95% CI) 83 (70, 93) 78 (64, 89) 80 (66, 90) 82 (67, 92)
1 BA Assay Cut-off Value: 0.03 ng/ml 2 CC Assay Cut-off Value: 0.15 ng/ml 3 AX Assay Cut-off Value: 0.40 ng/mlBMC Emergency Medicine 2004, 4:2 http://www.biomedcentral.com/1471-227X/4/2
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for analysis purposes to use the limit of detection (LoD)
for the three assays (0.03 ng/ml for the BA, 0.15 ng/ml for
the CC, and 0.4 ng/ml for the AX) in order to incorporate
both the indeterminate along with the positive cTnI val-
ues. This was done in order to more accurately reflect the
full spectrum of the AICS from micro infarct and unstable
angina to acute MI, whereby replicating how the results
are used clinically in the emergency department setting
[5,19,20,29]. This was not done in the manufacturers'
sponsored studies where the cut-off values used were the
Table 4: Patients with False Positive cTnI Results by Both Assay Pairs
Arm-1 (BA vs. CC)
Patient Diagnosis Creatinine mg/dL Age Sex Race
1 Liver failure, Hypokalemia 1.9 63 M W
2 Arrhythmia, Stable Angina 1.7 73 M W
3 Chronic Pain Syndrome, EtOH poisoning 0.6 61 M W
4 Arrhythmia, Hyperkalemia, Renal failure 6.8 72 M W
5 Uremia, Dehydration, Anemia 12.6 53 M H
6 Metastatic Cancer 0.8 85 M W
7 Bladder Cancer 2.3 77 M W
8 Anxiety 1.4 37 F B
Arm-2 (BA vs. AX)
Patient Diagnosis Creatinine mg/dL Age Sex Race
1 CHF, pneumonia 1.6 87 F W
2 GI Bleeding 2.1 82 F W
3 Depression 0.7 60 W M
4 Stable angina 0.9 70 W M
5 Stable angina 0.7 55 M W
6 Chest wall pain 0.8 42 F H
7 Anxiety 0.8 42 F H
8 CHF, Diabetes 1.0 85 F W
9 GI Bleeding, Diabetes 2.3 58 F B
Bland-Altman Transformation: BA vs CC (Arm-1) Figure 1
Bland-Altman Transformation: BA vs CC (Arm-1). 
Bland-Altman plot of cTnI for the BA and CC analyzers using 
transformed data.
Bland-Altman Transformation: BA vs AX (Arm-2) Figure 2
Bland-Altman Transformation: BA vs AX (Arm-2). 
Bland-Altman plot of cTnI for the BA and AX analyzers using 
transformed data.BMC Emergency Medicine 2004, 4:2 http://www.biomedcentral.com/1471-227X/4/2
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upper reference range limits (0.15 ng/ml for the BA, 1.4
ng/ml for the CC, and 1.9 ng/ml for the AX) for the detec-
tion of ST elevation MI. Unfortunately, no additional
manufacturer data are available to compare against the
AICS, a broader diagnostic entity. Despite using the lower
cut-off value for the CC analyzer, our study showed a
lower sensitivity compared to the manufacturer's value,
which cannot be easily explained, although a number of
causes of assay interference are discussed below. Similarly,
a decreased sensitivity was also seen with the AX analyzer,
but in this instance, there was considerable overlap of the
95%CI.
Serum specimens which are frozen for purpose of delayed
batch analysis undergo different handling procedures
than do fresh serum or plasma samples used for process-
ing in real-time analysis [9,10]. Freezing entails extra
centrifugation and settling steps that allow for potentially
more adequate clearance of micro-clots and bubbles from
the blood samples, both of which can contribute to an
over-estimation of cTnI quantity by the analyzer [30]. This
over-counting would result in an abnormally high, or
false positive value being obtained. Some of the cTnI assay
systems currently available (such as the CC assay system)
incorporate clot and bubble detection technology into
their processors to help minimize these confounding var-
iables, but their accuracy has not been well studied in real-
time clinical trials. Additionally, under real-time labora-
tory conditions, machines running multiple analytes in
random-access mode, may be subject to carry-over effects,
assay drift or sub-optimal reagent integrity resulting in
further result variation.
All currently marketed cTnI assays use unique antibodies
to cTnI epitopes, some of which are inherently less specific
than others [7,11,12]. The BA recognizes the C-terminal
portion (CTP) of cTnI, whereas the other assays recognize
the N-terminal portion (NTP) [31]. Shi et al. have shown
that there is preferential degradation of the CTP versus the
NTP of cTnI, leading to increased assay inaccuracy due to
under-estimation of cTnI. Yeo et al. concluded that the
superior performance of the AX system (which also lacks
the clot and bubble detection technology) over the BA
system, is possibly due to the use of a more specific cTnI
antibody with less heterophile antibody interference [12].
The numerous cTnI assays currently available do not con-
form to a recognized uniform standardization, as do the
Cardiac Troponin-T (cTnT) assays [28]. Because of une-
qual reactivity by the different cTnI antibodies, standardi-
zation becomes much more difficult. There are significant
variations, sometimes greater than 10-fold, in cTnI con-
centrations when measured by different assays in patients
experiencing an AMI [8,32,33]. This was also true in com-
paring the BA with the AX and CC assays where cutoff val-
ues were approximately 10× lower for the BA assay. Future
standardization of all cTnI assays by use of a common ref-
erence standard for cTnI, will be extremely important to
achieve comparability of test results between labs [34].
Such efforts are currently under way [35].
Recent studies have revealed a number of other factors
which may interfere with the interpretation of elevated
cTnI results. Elevated cTnI, especially in the lower ranges,
have been seen in patients suffering from acute illness
aside from the AICS such as HIV, chronic renal failure,
sepsis, cirrhosis, lung diseases, endocrine, muscular and
CNS disorders, and non-ischemic dilated cardiomyopa-
thies [36,37]. Fluid therapy may also interfere with cTnI
assays since dilution of the serum with saline, Plasmion (a
modified fluid gelatin), hydoxyethyl starch, and 20%
human albumin have been shown to interfere with cTnI
assay results [38]. Gerhardt et al. have shown that the use
of heparinized tubes for serum collection can lower
reported cTnI levels, especially early in the course of the
AICS disease process [39]. Also, heterophilic antibodies in
the serum of some individuals, have led to cases of
reported false positive cTnI results [12]. Unfortunately,
the routine screening for most of these interfering sub-
Table 5: Comparison of cTnI Sensitivity and Specificity Values to the Published Manufacturer's Values
Sensitivity (95%CI) Specificity (95%CI)
BA: Value in Arm-1: 97 (86, 100) 18 (9, 30)
Value in Arm-2: 100 (93, 100) 11 (4, 24)
Manufacturer's Values: 84 (66, 95) 93 (87, 97)
CC: Value (Arm-1): 63 (46, 78) 87 (76, 94)
Manufacturer's Values: 95 (82,98) 99 (97,100)
AX: Value (Arm-2): 83 (70, 93) 78 (64, 89)
Manufacturer's Values: 94 (83,99) 93 (89,96)
Arm-1 and Arm-2 AICS Cut-off Values: BA (0.03 ng/ml), CC (0.15 ng/ml), AX (0.40 ng/ml) Manufacturers' AMI Cut-off Values: BA (0.16 ng/ml), CC 
(1.41 ng/ml), AX (1.91 ng/ml)BMC Emergency Medicine 2004, 4:2 http://www.biomedcentral.com/1471-227X/4/2
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stances and diagnoses would render the clinical utility of
the cTnI assay impractical.
It is unclear as to why the distribution of indeterminate
BA-cTnI values for the AICS-positive patients is different
in the two study arms (21/38 (55%) in Arm-1 and 8/48
(17%) in Arm-2). This was likely due to an unidentified
variation in the patient populations since analysis showed
no time differences in assay processing or specimen han-
dling. In both arms of the study, the BA system demon-
strated excellent sensitivity but produced a high number
of potential false positive (53% and 44% respectfully)
results. The implications of a false positive as well as a
false negative cTnI result can be dramatic. False positives
will increase the costs associated with a patient's cardiac
evaluation by necessitating additional testing, potential
unnecessary hospitalization, iatrogenic morbidity, missed
time from work, and undue angst by all parties involved.
False negative results, as was seen with both the CC and
AX analyzers, may falsely reassure the treating clinician
leading to a missed diagnosis of the AICS with potentially
serious medical and legal consequences. In this era of cost
containment, a test which demonstrates a 100% negative
predictive value, as with the performance of the BA assay
system in this trial, is not desirable at the expense of a
markedly increased number of false positives which
would contribute greatly to the patient's healthcare
expenses. Physicians are reminded daily of the balance
between risks of inappropriate patient discharge and costs
associated with inpatient or observation unit cardiac
evaluations. Depending on the clinical circumstances, the
treating clinician may have a lower threshold to admit the
patient and a higher comfort level with a test demon-
strated to produce a higher sensitivity. Reliance on objec-
tive measurements of cardiac ischemia, such as cardiac
markers, must be taken in context with the patient's entire
clinical scenario, and, as better cardiac indicators become
available, their use will only increase. As this study shows,
there is an additional need for laboratories to more closely
collaborate with clinicians and work together to deter-
mine the most appropriate troponin clinical cut-off levels
and upper reference intervals.
Limitations
There are a number of limitations to this study. All
patients were at least eight hours from the onset of their
symptoms, and although the pharmacokinetics of cTnI
ensures that significantly elevated levels would remain
detectable for at least a week, the exact timing of the blood
draws were not standardized. Despite variability in phle-
botomy times, correlation with the AICS may have more
accurately replicated actual clinical use and interpretation
of the cTnI marker. Secondly, although we sought to pri-
marily compare the discrepancy of cTnI values obtained,
the criteria for determining the presence of the AICS were
based on objective as well as subjective assessment,
thereby allowing for some cases to be categorized by infer-
ence. Despite multiple objective criteria available to the
physician, labeling a patient's symptoms as having (or not
having) been cardiac in etiology incorporates "the art"
into medical practice. Although determining the analytic
capabilities of an assay is never without error (with the
subsequent calculation of sensitivity and specificity), we
feel our results were based on a reasonable AICS cardiac
endpoint. Thirdly, the laboratory's handling of the speci-
mens and assays may have resulted in some undetected
bias with regards to the manipulation of the samples.
Improperly collected or assayed specimens can dramati-
cally alter the results obtained, despite the use of auto-
mated assay systems. Fourthly, given the financial
restrictions of the project, no AX vs. CC arm was per-
formed, thus slightly limiting the conclusions of this
study. Fifthly, as newer generation assays become availa-
ble, clinicians must be attuned to their deficiencies, as has
been demonstrated here with the ACCESS first generation
assay system. Direct assay comparisons under real-time
conditions are warranted as new cTnI assays are marketed
[40]. Sixthly, in this study, each analyzer was dedicated to
running only the cTnI assay, and thus not subject to
potential confounders that may additionally appear when
machines are processing multiple analytes in a random-
mode access. Lastly, we did not control for hemodilution,
the presence of other illnesses or heterophilic antibodies,
all of which may potentially confound the cTnI levels
obtained as mentioned in more recent studies.
Conclusions
Assay systems currently available are clearly not equal in
their abilities to determine real-time quantitative cTnI val-
ues. Our results show that both the AX and the CC assay
systems performed much more accurately in their ability
to correlate with the diagnosis of the AICS than did the BA
system. The BA assay results did not correlate well with
clinical outcomes with regard to its positive predictive
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